



ALTERNATIVE TO PTO/SB/08 a/b (07-05)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/682,331		
		Filing Date	October 8, 2003		
		First Named Inventor	David L. SHELTON		
		Art Unit	1647		
		Examiner Name	J. Lockard		
Sheet	1	of	1	Attorney Docket Number	514712000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
I/JL	1.	ATCC Search Results for "911 Mab" located at < <a href="http://www.atcc.org/common/catalog/wordSearch/results.cfm">http://www.atcc.org/common/catalog/wordSearch/results.cfm</a> >, last visited August 30, 2006, one page.	
	2.	Berzofsky, J.A. et al. (1993). "Immunogenicity and Antigen Structure" Chapter 8 <i>In</i> Fundamental Immunology, Paul, W.E. ed., Raven Press: New York, NY, pg. 242.	
	3.	Kehlet, H. (April 1995). "Synergism Between Analgesics," <i>Ann. Med.</i> 27(2):259-262.	
	4.	Leem, J.W. et al. (2000). "Anti-NGF Treatment Suppresses Abnormal Pain Behaviors Induced After Spinal Cord Injury in the Rat," 30th Annual Meeting of the Society of Neuroscience, New Orleans, LA, November 4-9, 2000, <i>Society for Neuroscience Abstracts</i> 26(2):1690, Abstract No. 633.1.	
	5.	Sequence Alignments for Sequence Searches of SEQ ID NOS:1-8, pgs. 1-8.	
	6.	Sunshine, A. et al. (July 1987). "Analgesic Efficacy of Two Ibuprofen-Codeine Combinations for the Treatment of Postepisiotomy and Postoperative Pain," <i>Clin. Pharmacol. Ther.</i> 42(1):374-380.	
I/JL	7.	Supplementary European Search Report mailed September 12, 2006, for EP Application No. 03779091.2 filed October 3, 2003, four pages.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jon Lockard/	Date Considered	03/27/2007
-----------------------	---------------	--------------------	------------

pa- 1117741



ALTERNATIVE TO PTO/SB/08A/B (09/06)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/682,331	
			Filing Date	October 8, 2003	
			First Named Inventor	David L. SHELTON	
			Art Unit	1647	
			Examiner Name	J. Lockard	
Sheet	1	of	1	Attorney Docket Number	514712000400

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
/JL/	1.	WO-2006/077441-A1	07-27-2006	Cambridge Antibody Technology Limited et al.		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/JL/	2.	Fleischmann, R.M. et al. (2004). "Considerations With the Use of Biological Therapy in the Treatment of Rheumatoid Arthritis," <i>Expert. Opin. Drug Safety</i> 3(5):391-403.		
	3.	International Search Report for PCT Application No. PCT/US2006/013921 filed April 11, 2006, mailed January 2, 2007, seven pages.		
	4.	Lane, N. et al. (September 2005). "RN624 (Anti-NGF) Improves Pain and Function in Subjects with Moderate Knee Osteoarthritis: A Phase I Study," <i>Arthritis &amp; Rheumatism</i> 52(9-Suppl. S):S461, Abstract No. 1205.		
	5.	Orbach, H. et al. (December 2005). "Intravenous Immunoglobulin: Adverse Effects and Safe Administration," <i>Clinical Rev. Allergy Immunol.</i> 29(3):173-184, (Abstract Only,) one page.		
	6.	Seaver, S.S. (August 1994). "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought," <i>Genetic Engineering</i> 14(14):10, 21.		
	7.	Shelton, D.L. et al. (July 2005). "Nerve Growth Factor Mediates Hyperalgesia and Cachexia in Auto-Immune Arthritis," <i>Pain</i> 116(1-2):8-16.		
	8.	Stedman, T.L. (2000). "Definition of Osteoarthritis" <i>In Illustrated Stedman's Medical Dictionary</i> , Lippincott Williams & Wilkins: Baltimore, MD, 27th Edition, pg. 1282.		
	9.	Suntharalingam, G. et al. (September 7, 2006). "Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412," <i>New England Journal of Medicine</i> 355(10):1018-1029.		
/JL/	10.	Vastag, B. (June 2006). "Monoclonals Expand into Neural Disorders," <i>Nature Biotechnology</i> 24(6):595-596.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jon Lockard/	Date Considered	03/30/2007
-----------------------	---------------	--------------------	------------

pa-1128673

Replacement of  
9/25/04

ALTERNATIVE TO PTO/SB038a (07-05)

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/882,331		
		Filing Date	October 8, 2003		
		First Named Inventor	David L. SHELTON		
		Art Unit	1647		
		Examiner Name	J. Lockard		
Sheet	2	of	7	Attorney Docket Number	514712000400

JL	37.	WO-02/102232-A2, A3	12-27-2002	The Regents of the University of California		
	38.	WO-03/022261-A1	03-20-2003	Miller		
	39.	WO-2004/026329-A1	04-01-2004	Amgen, Inc.		
	40.	WO-2004/028448-A2, A3	04-08-2004	Miller		
	41.	WO-2004/032852-A2, A3	04-22-2004	Rinat Neurosciences Corp.		
	42.	WO-2005/019266-A2, A3	03-03-2005	Amgen, Inc.		
JL	43.	WO-2005/111077-A2, A3	11-24-2005	Rinat Neuroscience Corp. et al.		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T*
JL	44.	Abbadie, C. et al. (June 24; 2003). "Impaired Neuropathic Pain Responses in Mice Lacking the Chemokine Receptor CCR2," <i>Proc. Natl. Acad. Sci. USA</i> 100(13):7947-7952.				
	45.	Aloe, L. et al. (1993). "The Synovium of Transgenic Arthritic Mice Expressing Human Tumor Necrosis Factor Contains a High Level of Nerve Growth Factor," <i>Growth Factors</i> 9(2):149-155.				
	46.	Aloe, L. et al. (Sept.-Oct. 1999). "Nerve Growth Factor in the Synovia of Patients with Rheumatoid Arthritis: Correlation with TNF- $\alpha$ and IL-1 $\beta$ and Possible Functional Significance," <i>Clin. Exp. Rheumatol.</i> 17(5):632-633.				
	47.	Altschul, S.F. et al. (1997). "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," <i>Nucleic Acids Res.</i> 25(17):3389-3402.				
	48.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 5-7.				
	49.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 55-60.				
	50.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 66-69.				
	51.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 1, lines 41-44.				
	52.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 25-27.				
	53.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 32-33.				
	54.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 48-50.				
	55.	American Chemical Society (1987-1991). <i>Chemical Abstracts</i> , 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 52-53.				
	56.	Barbas III, C.F. et al. (April 1994). "In vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," <i>Proc. Natl. Acad. Sci. USA</i> 91:3809-3813.				
JL	57.	Barbas III, C.F. et al. (2001). "Vector pComb3X, Figure 2.2" In "Phage-Display Vectors" Chapter 2 In <i>Phage Display: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 2.9-2.13.				

Examiner Signature	/Jon Lockard/	Date Considered	09/16/2006
--------------------	---------------	-----------------	------------

pa-1064427